Telehealth payments

503A vs 503B Pharmacies: What Telehealth Merchants Need to Know Before Underwriting

The two compounding pathways in federal law ask different things of the pharmacy, which means they ask different things of your merchant file.

By VyaPayPublished 6 min read

A 503A pharmacy is a state-licensed pharmacy that compounds on a valid prescription for an identified patient. A 503B outsourcing facility registers with FDA, works under current good manufacturing practice, is inspected by FDA, reports its products, and can compound with or without a prescription. For a telehealth merchant, the difference decides which licenses, registrations and records your underwriter asks to see.

A 503A compounding pharmacy is a state-licensed pharmacy that compounds drugs under section 503A of the Food, Drug, and Cosmetic Act (21 U.S.C. 353a). It compounds on a valid prescription for an identified individual patient, and it may not compound essentially copies of commercially available drugs regularly or in inordinate amounts. Section 503A also covers compounding by licensed physicians.

What's the difference between 503A and 503B?

One is built around the individual prescription, the other around FDA registration and manufacturing-style oversight. The statutes line up like this:

503A pharmacy503B outsourcing facility
Federal lawFD&C Act §503A, 21 U.S.C. 353aFD&C Act §503B, 21 U.S.C. 353b
Who it isA state-licensed pharmacy or physicianA facility registered with FDA as an outsourcing facility
PrescriptionsCompounds on a valid prescription for an identified patientMay compound with or without prescriptions, for example for office use
CGMPNot a §503A conditionRequired
FDA inspectionNot a §503A conditionSubject to FDA inspection
Reporting to FDANot a §503A conditionReports its products to FDA
Copies of approved drugsMay not compound essentially copies regularly or in inordinate amountsFDA's shortage-based allowance for GLP-1 copies ended on separate 503B dates

"Not a §503A condition" means only that the statute's 503A conditions don't include it. It doesn't mean a 503A pharmacy is unsupervised: it holds a state license, and its state's rules apply to it.

Which kind of pharmacy does a telehealth program use?

Either can appear, and your file needs to say which. A program whose clinicians prescribe for individual patients fits the 503A description directly. A 503B facility can also sit behind a telehealth program, since it may compound with or without prescriptions. The useful question isn't which pathway is better. It's which one your pharmacy actually operates under, and whether your model fits it.

If your pharmacy only dispenses FDA-approved, manufactured products, the 503A and 503B question doesn't arise for those products at all. It comes back the moment you add a compounded product to the menu, and so does your underwriter's interest.

What an underwriter asks for, pathway by pathway

Proof that the pharmacy is what it says it is, and that your products fit its pathway. Our reading of what each pathway implies for the file:

If your pharmacy operates under §503A

  • The pharmacy's state license and the name of its pharmacist-in-charge, plus any non-resident licenses it holds for the states it ships into.
  • A de-identified walk-through of how a prescription moves from your clinician to the pharmacy for one patient, showing that each fill is tied to an individual prescription.
  • The compounded product list, by active ingredient as it appears on the label.
  • For each GLP-1 product, the pharmacy's position on the essentially-copies limit, reviewed by its counsel or yours.

If your pharmacy is a §503B outsourcing facility

  • Its FDA outsourcing-facility registration.
  • Its most recent FDA inspection outcome and any FDA correspondence about the products you sell.
  • Confirmation that it reports the products you buy to FDA.
  • Whether each product is compounded from bulk drug substances, given FDA's pending bulks-list proposal (below).

Either way

  • The supply contract, naming the pharmacy that makes the product.
  • A sample label showing that same pharmacy.
  • Who charges the patient for the medication: you or the pharmacy.

How the GLP-1 shortage decisions apply to each pathway

FDA gave the two pathways different transition dates, and both have passed. For tirzepatide, FDA's enforcement-discretion period ended on February 18, 2025 for 503A compounders and March 19, 2025 for 503B outsourcing facilities. For semaglutide, the dates were April 22, 2025 and May 22, 2025. After those dates, FDA's position is that compounders under either pathway can no longer rely on the shortage to make essentially copies of the approved drugs.

Two later developments split by pathway. FDA has proposed, in a Federal Register notice reported on May 1, 2026, not to place semaglutide, tirzepatide and liraglutide on the 503B bulks list, which matters to outsourcing facilities only; it wasn't final as of November 2026 as far as we know. FDA's statement that it is "not aware of any lawful basis" for compounding with salt forms such as semaglutide sodium or acetate isn't limited to one pathway. The full timeline is in what FDA has said about compounded GLP-1s.

Where does the pharmacy sit in your payment flow?

Either it charges the patient, or you do and pay it. That choice decides whose merchant account the medication runs through.

When the pharmacy charges the patient, the sale is the pharmacy's, under MCC 5912 and its own network registrations, and your account carries the consult and membership fees. We cover the pharmacy side in online pharmacy merchant accounts. When you charge for the medication, you are selling prescription drugs yourself, and in our reading your underwriter will need the pharmacy's file as part of yours, because your account's risk now includes the pharmacy's. If your company or its owners hold any stake in the pharmacy, say so up front.

VyaPay runs its own processor and underwrites in-house, so the pharmacy questions and the payment-flow questions are answered in one review by the team that makes the underwriting call. The rest of a weight-loss program's file is in payment processing for GLP-1 telehealth, and you can talk to us about your pharmacy model before you apply.

Red flags in a pharmacy relationship

Anything suggesting the product, the label or the seller isn't what it appears to be. These are drawn from FDA's and LegitScript's own statements:

  • A supplier describing its product as "research use only" or "not for human consumption". LegitScript lists research-use-only chemical businesses, including peptide sellers, as generally not eligible for its certification.
  • A label naming a pharmacy that doesn't exist or didn't make the product, which FDA says it has seen on compounded GLP-1s.
  • Branding that implies your telehealth company is the compounder, a claim FDA's warning letters to telehealth sellers cited.
  • A salt form of semaglutide on the label.
  • A price that seems too good to be true, which FDA also lists as a red flag.

Frequently asked questions

Is a 503B outsourcing facility safer than a 503A pharmacy?

We don't make clinical or safety comparisons. The statutory differences are FDA registration, CGMP, FDA inspection and product reporting for 503B facilities, and underwriters read those as documentation to check, not as a safety rating.

What is a GLP-1 compounding pharmacy?

Shorthand for a 503A pharmacy or 503B outsourcing facility that compounds GLP-1 drugs such as semaglutide or tirzepatide. Since FDA's 2025 transition dates passed, FDA's position is that such pharmacies can't rely on the shortage to make essentially copies, so expect an underwriter to ask about the basis for each product.

Does a 503A pharmacy need a prescription for every compounded drug?

Section 503A describes compounding based on a valid prescription for an identified patient, which is why underwriters ask to see how your prescriptions reach the pharmacy. Questions about any exceptions belong with the pharmacy's counsel.

Do I need to tell my processor if I change pharmacies?

Yes. The pharmacy was part of what was underwritten, so a new one changes the file. LegitScript also asks certified businesses to tell it about new partners.

Sources

Talk to the team that underwrites you

Tell us what you prescribe or sell, how you bill and who your pharmacy partners are. You'll be talking to the people who run VyaPay's processor and make its risk decisions.

or call 833-4-VYAPAY

Let’s meet up!

Tell us about your business and someone from our team will reach out.